Breaking
Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect ProgramEli Lilly's Legal Victory Over Noom's GLP-1 ClaimsBBSW AI Solution Event: Daily Roundup
Monday, June 8, 2026
🇺🇸 FDA

GIP News

🇺🇸 Americas ← All news

FDA GIP coverage for business development, investment, and market access teams

Latest on GIP

GLP-1 usage statistics show broad uptake and mixed clinical signals
NewsGLP-1Jun 7, 2026

GLP-1 usage statistics show broad uptake and mixed clinical signals

GLP-1 usage statistics show that 4.5% of participants reported using a GLP-1 or GLP-1/GIP medication in the past year, with 2.9% using it for weight loss. New research also highlights meaningful benefits alongside kidney, pancreas, and gastrointestinal risks, shaping the latest research on GLP-1 for pharma teams.

Dr. Sarah Mitchell

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.